LGTX-101 / LabGenius Therapeutics - LARVOL DELTA

A novel machine-learning derived nectin-4 x CD3 bispecific T-cell engager, LGTX-101, demonstrates high degrees of tumor selectivity and potently induces tumor regression in vivo (AACR 2026) - "LGTX-101 is a highly selective and highly efficacious Nectin-4 x CD3 TCE currently in preclinical development for treatment of advanced solid tumors. With an increased selectivity and potency profile, LGTX-101 has the potential to provide a safer, more effective treatment option for patients."

Bispecific • Machine learning • Preclinical • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NECTIN4

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025 (Businesswire) - "LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE)....For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA, was used to discover and concomitantly optimise a TCE with improved killing selectivity, potency, efficacy, and manufacturability."

Preclinical • Oncology